Lyxumia, Sanofi’s newly approved Type 2 diabetes drug could become a blockbuster, although it is the fourth drug in its class to come to market, insists David Solomon, CEO of Zealand Pharma AS, which discovered the drug and licensed it in 2003 to a company that Sanofi later acquired.
The competition isn’t a hurdle because the market for glucagon-like peptide 1 agonists, the class of drugs including Lyxumia (lixisenatide),...